2nd Quarter/FY2016 ending in March 2017 Consolidated Financial Results
9/20 Healthcare Business
【テロップ】
※各テロップ文字をクリックすると該当の場所がピンポイントで閲覧できます。
00:17:39.0
Next is the Healthcare Business. Revenue was up YoY, excluding the impact of exchange rates during the second quarter. This was owing in part to the acquisition of Viztek in the US. Business contribution profit was 1 billion yen for the three-month period of the second quarter. DR sales, which we are currently focusing on, were particularly strong in the US. Meanwhile, we were able to establish a genre-top position in the Japanese orthopedic surgery field in the diagnostics ultrasound business, which we are focusing on in Japan. We will enhance this strength in diagnostics ultrasound systems for orthopedic surgery overseas from the second half of the second quarter going into the second half. Medical IT services have also been strong due in part to the acquisition of Viztek, and we will further expand these services in the second half.However, looking at the second quarter, there are concerns such as weak CR sales in the US due in part to a revision of medical treatment fees, and we recognize that CR is not strong in Brazil, etc. Accordingly, we will introduce new products in this field in order to strengthen the DR series for the second half. We will introduce these new products at a slightly lower price range, and grow them during the second half.
【ノート】
